2-aMino-N-[1-(phenylMethyl)-4-piperidinyl]-benzeneMethanaMine
|
- $248 - $784
- Product name: 2-aMino-N-[1-(phenylMethyl)-4-piperidinyl]-benzeneMethanaMine
- CAS: 79099-03-9
- MF: C19H25N3
- MW: 295.42
- EINECS:
- MDL Number:MFCD20257749
- Synonyms:2-aMino-N-[1-(phenylMethyl)-4-piperidinyl]-benzeneMethanaMine;N-[(2-Aminophenyl)methyl]-1-benzylpiperidin-4-amine;N-(2-AMinobenzyl)-1-benzylpiperidin-4-aMine;4-Piperidinamine, N-[(2-aminophenyl)methyl]-1-(phenylmethyl)-
3 prices
Selected condition:
Brand
- AK Scientific
- Crysdot
- Matrix Scientific
Package
- 500mg
- 5g
- ManufacturerAK Scientific
- Product number9804AE
- Product descriptionN-[(2-Aminophenyl)methyl]-1-benzylpiperidin-4-amine
- Packaging500mg
- Price$384
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11056291
- Product descriptionN-(2-Aminobenzyl)-1-benzylpiperidin-4-amine 95+%
- Packaging5g
- Price$784
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number101459
- Product descriptionN-[(2-Aminophenyl)methyl]-1-benzylpiperidin-4-amine >97%
- Packaging500mg
- Price$248
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 9804AE | N-[(2-Aminophenyl)methyl]-1-benzylpiperidin-4-amine | 500mg | $384 | 2021-12-16 | Buy |
| Crysdot | CD11056291 | N-(2-Aminobenzyl)-1-benzylpiperidin-4-amine 95+% | 5g | $784 | 2021-12-16 | Buy |
| Matrix Scientific | 101459 | N-[(2-Aminophenyl)methyl]-1-benzylpiperidin-4-amine >97% | 500mg | $248 | 2021-12-16 | Buy |
Properties
Boiling point :452.7±45.0 °C(Predicted)
Density :1.11±0.1 g/cm3(Predicted)
pka :9.09±0.20(Predicted)
Density :1.11±0.1 g/cm3(Predicted)
pka :9.09±0.20(Predicted)
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||
| Precautionary statements: |
|




